Arcus Biosciences RCUS Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Summit TherapeuticsSMMT

——

ExelixisEXEL

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's proceeds from exercises of stock options and other stock issuances?: Arcus Biosciences (RCUS) reported proceeds from exercises of stock options and other stock issuances of $3M in Q1 2026.
What is the long-term trend for Arcus Biosciences's proceeds from exercises of stock options and other stock issuances?: Over 4 years (2021 to 2025), Arcus Biosciences's proceeds from exercises of stock options and other stock issuances has grown at a -4.5% compound annual growth rate (CAGR), from $12M to $10M.